Merck & Company Inc (MRK)vsScienture Holdings, Inc. (SCNX)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
SCNX
Scienture Holdings, Inc.
$0.39
+5.08%
HEALTHCARE · Cap: $15.56M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 15062340% more annual revenue ($65.01B vs $431,610). MRK leads profitability with a 28.1% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
SCNX
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+15.5%
Fair Value
$0.53
Current Price
$0.39
$0.14 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 1870.0%
Revenue surging 810.0% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -55.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : SCNX
The strongest argument for SCNX centers on Price/Book, Operating Margin, Revenue Growth. Revenue growth of 810.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : SCNX
The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while SCNX is a hypergrowth play — different risk/reward profiles.
SCNX is growing revenue faster at 810.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 43/100), backed by strong 28.1% margins. SCNX offers better value entry with a 15.5% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Scienture Holdings, Inc.
HEALTHCARE · PHARMACEUTICAL RETAILERS · USA
Scienture Holdings, Inc. (SCNX) is a biotechnology company dedicated to advancing therapeutic solutions for neurological disorders through its innovative drug development pipeline. Leveraging cutting-edge technology and a highly proficient research team, Scienture aims to address significant unmet medical needs while enhancing patient outcomes. The company's unwavering commitment to scientific excellence, regulatory adherence, and strategic partnerships not only fuels its growth prospects but also underscores its potential to deliver impactful contributions to global healthcare advancements. As the healthcare sector continues to expand, SCNX is well-positioned to capitalize on emerging opportunities in the neurological treatment landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?